

# HIV PREVENTION RESEARCH & DEVELOPMENT INVESTMENT:

## State of the Funding in 2015


*Investment priorities to fund innovation in an evolving global health and development landscape*

July 2016

[www.hivresourcetracking.org](http://www.hivresourcetracking.org)

*Preliminary data*

### Global HIV Prevention R&D Investment by Technology Category




\*Tracking funding for female condom and treatment as prevention research began in 2010 \*\*Tracking funding for prevention of vertical transmission began in 2008 \*\*\* Tracking funding for PrEP began in 2002 \*\*\*\* Tracking funding for adult male circumcision began in 2001

### 2015 HIV Prevention R&D Funding Trends

In 2015, reported funding for HIV prevention R&D decreased from US \$ 1.26 billion in 2014 to US\$1.18 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC, declined. Prevention of vertical transmission remained almost flat-funded in 2015.

### Top Five Countries Investing in HIV Prevention R&D, by Technology Category 2015 (US\$ millions)




### Methodology

Since 2000, the Resource Tracking for HIV Prevention R&D working group (formerly the HIV Vaccines & Microbicides Resource Tracking Working Group) has employed a comprehensive methodology to track trends in research and development (R&D) investments and expenditures for biomedical HIV prevention options.

# 2015 HIV Prevention Research Trends


1) The **US public sector** remained the single largest source of funding for HIV prevention R&D, with a total investment of US\$836 million.

**US Public-Sector Investment in HIV Prevention R&D 2012 - 2015 (US\$ millions)**



2) **European public-sector** investment continued its decade-long decline, falling US\$8 million from 2014.

**European Public-Sector Investment in HIV Prevention R&D 2012 - 2015**



3) **Public-sector funding** outside the US and Europe also decreased, falling another US\$5 million in 2015, down to \$47 million.

Funding reductions of over 40% were seen in VMMC (89% decline) and microbicides (45% decline), while funding for PrEP, and TasP also decreased by 26% and 16% respectively.

Funding for preventive vaccines remained almost unchanged at US\$26 million. Prevention of vertical transmission and female condoms experienced a boost in funding thanks to new investments from India (female condoms implementation research) and from Australia, Brazil, Canada, and South Africa (prevention of vertical transmission).

4) In 2015 the **philanthropic sector** comprised 13% of all funding at US\$155 million, a 23% decrease from 2014 contributions, while the **commercial sector** increased its contribution to HIV prevention R&D by 19%.

**HIV Prevention R&D Trial Participants by Region in 2015**

**Total: 869,015**

